

Press Release

For Immediate Dissemination

Glenmark receives US FDA approval for the first generic version of Trileptal – Oxcarbazepine – Shared Exclusivity

Mumbai, October 10, 2007: Glenmark Pharmaceuticals Ltd. [Glenmark], a research-based pharmaceutical company, headquartered in Mumbai (India), has received final approval from the U.S. Food and Drug Administration for the marketing the first generic version of Trileptal (Oxcarbazepine). The approval is for marketing Oxcarbazepine tablets in three strengths – 150 mg, 300 mg and 600 mg.

Glenmark was one of the first ANDA applicants to submit a Paragraph IV certification to the '525 patent'. Therefore, with this approval, Glenmark has been awarded for 180 days of shared generic drug exclusivity for these strengths.

Trileptal is a widely used medication to treat epilepsy that has FDA approval.

Oxcarbazepine sales were approximately US\$643 million, for the 12-month period ending June 30, 2007, according to IMS Health.

With this approval, GPI now has a portfolio of 20 generic products for the US market and has over 35 ANDAs undergoing US FDA approval process/launch.

About Glenmark Pharmaceuticals Inc., USA [GPI]

Glenmark's US subsidiary, Glenmark Pharmaceuticals Inc., USA [GPI], was established in 2003 to enter into the world's largest pharmaceutical market. GPI is responsible for sales and marketing of generic drug formulations in the USA as well as APIs to customers in the regulated markets. GPI closed last Fiscal year with sales of USD 50 Mn from its formulations business.

About Glenmark

Glenmark Pharmaceuticals Ltd. is a research-led, global, fully integrated pharmaceutical company headquartered in Mumbai, India. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc] and metabolic disorders [Diabetes, Obesity, etc].

The Company has generic formulation and API business interests in over 80 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT, Diabetes and Oncology.

Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing



Glenmark House
HDO – Corporate Building, Wing A
B. D. Sawant Marg, Chakala
Off Western Express Highway,
Andheri [East], Mumbai 400 099, India
Tel.: 91-22 6758 9999
Email: media@glenmarkpharma.com

Phase II clinical trials in the US. The Company's second lead GRC 8200, a DPP-IV inhibitor for Type II Diabetes was out-licensed to Merck KGaA, Germany for the North American, European and Japanese markets. A third molecule targeting pain, GRC 6211, is undergoing Phase II clinical trials in Europe. Glenmark has three other programmes across obesity, inflammation and pain management at the pre-clinical stages; all of which should enter the clinics in by H1 FY 2008. www.glenmarkpharma.com

For further information, please contact:

Ms. Vasudha Jha
General Manager, Corporate Communications
Glenmark Pharmaceuticals Ltd.
Tel: [+91 22] 67589919 | Fax: [+91 22] 67589986
Email: media@glenmarkpharma.com